Literature DB >> 8799846

Modulation of osteoblast behaviour by tenascin.

E J Mackie1, S Ramsey.   

Abstract

The extracellular matrix protein tenascin is secreted by osteoblasts but absent from mineralized bone matrix. The current study was undertaken to test the hypothesis that tenascin regulates osteoblast behaviour. Three osteoblast-like cell lines UMR-106, ROS-17/2.8 (rat) and SAOS-2 (human) were used to investigate the role of tenascin in osteoblast morphology, differentiation and proliferation. Two of three cell lines adhered specifically to tenascin, remaining round and failing to spread. Tenascin as a substratum stimulated alkaline phosphatase activity (a marker of osteoblast differentiation) in two of three cell lines. Moreover, anti-tenascin in the medium caused a reduction in alkaline phosphatase levels in all three cell lines. Anti-tenascin also inhibited collagen synthesis, an important osteoblast function. Since it seemed possible that tenascin may exert its effects on cell function through its ability to cause cell rounding, the ability of cell shape change alone to influence alkaline phosphatase levels was investigated. Cells were incubated in the presence of cytochalasin D and alkaline phosphatase levels assayed. Alkaline phosphatase activity was not elevated by cytochalasin D treatment, indicating that cell rounding alone is insufficient to mimic the effect of tenascin. Anti-tenascin caused a slight increase in proliferation of SAOS-2 cells, indicating that tenascin is itself inhibitory. In ROS 17/2.8 and UMR-106 cells, in contrast, proliferation was inhibited by anti-tenascin. The results presented here indicate that tenascin is able to stimulate osteoblastic differentiation and that endogenous tenascin helps to maintain the functional state of cultured osteoblast-like cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799846     DOI: 10.1242/jcs.109.6.1597

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  8 in total

1.  Regulation of tenascin expression in bone.

Authors:  Jessica M Morgan; Alice Wong; Clare E Yellowley; Damian C Genetos
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

2.  Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis.

Authors:  B Jian; P L Jones; Q Li; E R Mohler; F J Schoen; R J Levy
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats.

Authors:  N Vyavahare; P L Jones; S Tallapragada; R J Levy
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

4.  Study of the in vitro corrosion behavior and biocompatibility of Zr-2.5Nb and Zr-1.5Nb-1Ta (at%) crystalline alloys.

Authors:  F Rosalbino; D Macciò; P Giannoni; R Quarto; A Saccone
Journal:  J Mater Sci Mater Med       Date:  2011-04-02       Impact factor: 3.896

5.  The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation.

Authors:  S Schenk; R Chiquet-Ehrismann; E J Battegay
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

Review 6.  The effect of five proteins on stem cells used for osteoblast differentiation and proliferation: a current review of the literature.

Authors:  P Chatakun; R Núñez-Toldrà; E J Díaz López; C Gil-Recio; E Martínez-Sarrà; F Hernández-Alfaro; E Ferrés-Padró; L Giner-Tarrida; M Atari
Journal:  Cell Mol Life Sci       Date:  2013-04-09       Impact factor: 9.261

7.  Identification of proteins with potential osteogenic activity present in the water-soluble matrix proteins from Crassostrea gigas nacre using a proteomic approach.

Authors:  Daniel V Oliveira; Tomé S Silva; Odete D Cordeiro; Sofia I Cavaco; Dina C Simes
Journal:  ScientificWorldJournal       Date:  2012-05-01

8.  The pathophysiological basis of pharmacological interventions in CAVD.

Authors:  P W Riem Vis; J-W van Rijswijk; S A J Chamuleau; A Vink; L A van Herwerden; J Kluin
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.